NASDAQ:CAPS Capstone Therapeutics Q2 2026 Earnings Report $0.14 -0.01 (-7.40%) Closing price 04:00 PM EasternExtended Trading$0.14 +0.00 (+0.69%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Capstone Therapeutics EPS ResultsActual EPSN/AConsensus EPS $0.12Beat/MissN/AOne Year Ago EPSN/ACapstone Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$20.39 millionBeat/MissN/AYoY Revenue GrowthN/ACapstone Therapeutics Announcement DetailsQuarterQ2 2026Date8/12/2026TimeBefore Market OpensConference Call DateWednesday, August 12, 2026Conference Call Time9:30AM ETConference Call ResourcesSlide DeckPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfileSlide DeckFull Screen Slide DeckPowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Capstone Therapeutics Earnings HeadlinesCapstone Therapeutics Corp. (NASDAQ:CAPS) Short Interest UpdateSeptember 30 at 5:21 AM | americanbankingnews.comReviewing Capstone Therapeutics (NASDAQ:CAPS) and Marwynn (NASDAQ:MWYN)September 28 at 5:14 AM | americanbankingnews.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.September 30 at 1:00 AM | The Oxford Club (Ad)Head to Head Review: Mitsui & Co. (OTCMKTS:MITSY) and Capstone Therapeutics (NASDAQ:CAPS)September 24, 2026 | americanbankingnews.comCapstone Publishes Investor FAQ: 75% of Convertible Note Principal Retired, Approximately $1.72 Million RemainingAugust 26, 2026 | businesswire.comCapstone Reports Q2 2026 Results: Revenue Up 67%, Gross Profit Up 92%, Stone Business Adjusted EBITDA Turns Positive as GuidedAugust 12, 2026 | businesswire.comSee More Capstone Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Capstone Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Capstone Therapeutics and other key companies, straight to your email. Email Address About Capstone TherapeuticsCapstone Therapeutics (NASDAQ:CAPS) Corporation was a U.S.-based biotechnology company focused on developing peptide-based therapies for diseases involving fibrosis, scarring and abnormal tissue repair. Publicly available information about the company’s current operations is limited. Its principal disclosed product candidate was AZX100, a synthetic peptide designed to influence cellular pathways associated with scar formation and fibrotic disease. The candidate was investigated for potential applications involving conditions such as dermal scarring and pulmonary fibrosis, although the available historical information does not establish a currently marketed product. Capstone Therapeutics was based in the United States and appeared to operate primarily as a development-stage pharmaceutical company rather than as a commercial drug manufacturer. Reliable, up-to-date information about its current leadership, geographic operations and corporate status is not readily available.View Capstone Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Deutsche Bank Makes a Contrarian Call on Netflix—What Does It Mean for Investors?CarMax Just Gave Investors a Better Reason to Believe in the TurnaroundArhaus Has New Momentum—Could Other Furniture Stocks Be Next?Bernstein Downgrades 3 Cybersecurity Stocks: How Concerned Should Investors Be?Brewing Trouble? Starbucks Spills the Beans on 250 Store ClosuresMarketBeat Week in Review – 09/21 - 09/25Analyst Rating Boosts May Signal More Upside for These 3 Stocks Upcoming Earnings NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
